StonvexLoading…
StonvexStonvexStonvexCore line items from ACVA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2023 2023-09-30 | Q2 2023 2023-06-30 | Q1 2023 2023-03-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $3.80M | $3.80M | $3.80M | $3.80M |
Operating Income | $-62.91M | $-40.62M | $-20.83M | $-106.21M |
Net Income | $-52.02M | $-33.78M | $-18.20M | $-102.19M |
EPS (Diluted) | $-0.33 | $-0.21 | $-0.11 | $-0.65 |
Total Assets | $959.08M | $936.42M | $995.15M | $914.92M |
Total Liabilities | $491.99M | $460.25M | $514.24M | $429.20M |
Cash & Equivalents | $226.24M | $271.95M | $317.15M | $280.75M |
Free Cash Flow OCF − CapEx | $7.09M | $22.48M | $42.71M | $-78.39M |
Shares Outstanding | 159.54M | 159.09M | 158.69M | 156.99M |